Assessing Medication Confounders Before Determination of Brain Death/Death by Neurologic Criteria: A Primer, with Opioids as a Worked Example

PURPOSE: To provide a primer on how clinicians, particularly pharmacists, can systematically assess whether a medication may confound determination of brain death/death by neurologic criteria (BD/DNC), using pharmacokinetic and pharmacodynamic principles that can be applied to any agent with the aid of tertiary references, and using opioids as a worked example. SUMMARY: All major guidelines require exclusion of central nervous system (CNS) depressant effect before BD/DNC determination, yet none provides a general method for deciding when a given medication has cleared. Rather than cataloging every agent, this primer sets out the parameters that govern how long any drug can suppress the neurologic examination: lipophilicity and volume of distribution, elimination pathway and the effect of hepatic or renal dysfunction, active metabolites, and the context-sensitive half-life, which lengthens with the duration of an infusion and is not predicted by the elimination half-life. Special states, including obesity, hypothermia, extracorporeal support, and overdose, further prolong effect; in overdose, delayed absorption and saturable elimination can invalidate the customary five-half-life rule. Routine toxicology screens miss many relevant substances, including synthetic opioids. Opioids illustrate the framework across three common scenarios: exposure before arrival, continuous infusion, and overdose. CONCLUSION: No validated serum concentration threshold defines clearance for most CNS depressants, and the safest determination rests on structured pharmacokinetic reasoning, toxicology consultation, and institutional protocols that specify how confounders are screened for and excluded, rather than on any single number or fixed waiting period.